# Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

> **NCT02681562** · PHASE2 · UNKNOWN · sponsor: **Istituti Ospitalieri di Cremona** · enrollment: 45 (actual)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** olaparib

## Key facts

- **NCT ID:** NCT02681562
- **Lead sponsor:** Istituti Ospitalieri di Cremona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2018-01
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681562, "Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02681562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*